drugset
drugset / Trial / NCT02277457

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

NCT02277457 ↗

Phase 0 Withdrawn University of Michigan Rogel Cancer Center Augusta University · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Hypotheses: Short-term - Targeted therapy with erlotinib or crizotinib plus PART (Personalized Adaptive Radiation Therapy) will be safe and will yield favorable outcomes in patients with stage III, EGFR (Epidermal Growth Factor Receptor) + or ALK (Anaplastic Lymphoma Kinase) + NSCLC (Non-Small Cell Lung Cancer). Long-term - In patients with stage III NSCLC harboring driver mutations, treatment with relevant targeted agents plus PART will improve both local-regional and systemic tumor control resulting in improved survival relative to standard chemoradiotherapy.

Timeline

Start
2015-09
Primary completion
2021-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Crizotinib Small molecule 250 mg Oral
Subject Erlotinib Small molecule 150 mg Oral

Indications

non-small cell lung carcinoma